Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

112.39 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
56 57 Next >
Why Is Gilead Sciences Stock Trading Lower Today?
Gilead Sciences' global enrollment pause in magrolimab solid tumor studies. FDA issues partial clinical hold. Explore the impact on ongoing trials. 
Via Benzinga
Exposures Product Safety
When you look at NASDAQ:GILD, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
When you look at GILEAD SCIENCES INC (NASDAQ:GILD), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts. 
Via InvestorPlace
Gene therapy: Why does it cost millions for a single treatment?
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. 
Via MarketBeat
Exposures Product Safety
Analysts see over 50% gains in these 2 mid-cap biotech stocks
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Is NASDAQ:GILD a Good Fit for Dividend Investing?
Analyzing GILEAD SCIENCES INC (NASDAQ:GILD)'s Dividend Potential. 
Via Chartmill
$1000 Invested In This Stock 20 Years Ago Would Be Worth $10,000 Today
Via Benzinga
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst
Gilead's acquisition of CymaBay Therapeutics for $4.3 billion strengthens its liver disease portfolio. Analysts see potential in seladelpar's impact on PBC and pruritus, projecting peak sales of $800... 
Via Benzinga
Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded up 0.48% to 38,856.99 while the NASDAQ rose 0.26% to 16,031.87. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Masonite International Corporation (NYSE – DOOR), ZeroFox Holdings, Inc. (Nasdaq – ZFOX), RayzeBio, Inc. (Nasdaq – RYZB)
From Brodsky & Smith LLC
Via GlobeNewswire
Why is CymaBay (CBAY) Stock Up 25% Today?
CymaBay stock is rising higher on Monday as CBAY investors react to a $4.3 billion acquisition deal with Gilead Sciences. 
Via InvestorPlace
Health Care Company Gilead Sciences Announces Acquisition of CymaBay Therapeutics
Via Benzinga
Drugmaker Gilead Sciences Scoops Up Liver-Disease Focused CymaBay Therapeutics For $4.3B
Gilead Sciences will acquire CymaBay Therapeutics for $4.3 billion, advancing liver disease treatment with seladelpar. FDA priority review was granted, and there is potential for significant revenue... 
Via Benzinga
Exposures Product Safety
CymaBay Stock Rockets After Gilead Sciences Unveils $4.3 Billion Acquisition
The company is working on a treatment for primary biliary cholangitis, a liver disease treatment. 
Via Investor's Business Daily
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Stock Approaches Daily Buying Area
Gilead Sciences, Inc. is an US American biopharmaceutical company. It focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and... 
Via Talk Markets
Exposures COVID-19
Gilead-Backed Kyverna Overshoots Raised IPO Expectations
Kyverna Therapeutics raised almost $320 million in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences, the company's offering was the second largest for a... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC
From Gilead Sciences, Inc.
Via Business Wire
Top 5 Health Care Stocks That Are Preparing To Pump In February
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Stock Market Hits Highs As AI Plays Arm, Palantir Skyrocket: Weekly Review
The S&P 500 hit 5,000. Arm, Palantir and Cloudflare rose sharply. 
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
7 Biotech Stocks Fighting America’s Deadliest Diseases
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship. 
Via InvestorPlace
Why Gilead Sciences Stock Dropped Today
Gilead missed revenue estimates with its latest quarter and issued underwhelming 2024 guidance. 
Via The Motley Fool
S&P 500 Flirts With 5,000 As Magnificent 7 Tops $13 Trillion, NYCB Sinks: What's Driving Markets Wednesday?
Wednesday is a bullish day on Wall Street, with major large-cap indices extending record highs, aided by robust corporate earnings. Despite the overall market optimism, concerns linger within segments... 
Via Benzinga
Topics Stocks
Exposures US Equities
2 Beaten-Down Dividend Stocks to Buy Hand Over Fist
These stocks aren't value traps. 
Via The Motley Fool
Late-Session Earnings Bonanza: Ford, Chipotle, Snap & More
The Dow gained +141 points, +0.37%, while the S&P gained +0.23%. The Nasdaq, while positive, was essentially flat at +0.07%, while the small-cap Russell won the day, +0.85%, and continues inching its... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Gilead Sciences (GILD) Q4 2023 Earnings Call Transcript
GILD earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Gilead Sciences Stock Is Trading Lower After The Bell
Gilead Sciences shares are trading lower in Tuesday's after-hours session after the company reported weak earnings results and issued soft guidance. 
Via Benzinga
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend
From Gilead Sciences, Inc.
Via Business Wire
Gilead Rode An Unexpected Source For Its Sales Beat, But Profit Came Up Short
Gilead reported slightly better-than-expected fourth-quarter sales, while earnings and profit guidance lagged. 
Via Investor's Business Daily
Topics Earnings
Exposures Financial
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.